SCHEMBL1437280

SCHEMBL1437280

COc1ccc(Cl)cc1-c1c(C(N)=O)nc(-c2ccc(C)c(C)c2)n1-c1cc(Cl)ccc1C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 6/20 0.48
SLC9A1 P19634 2/20 0.39
HPGD P15428 3/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 1/20 0.39
TP53 P04637 3/20 0.39
MAPK1 P28482 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
ESR1 P03372 1/20 0.39
MAPT P10636 1/20 0.39
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MPO P05164 1/20 0.37
TPO P07202 1/20 0.37
JAK2 O60674 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1437262 0.91 MDM2 (0.59) MDM2HPGDALDH1A1TP53MAPK1
SCHEMBL9893829 0.90 MDM2 (0.61) MDM2SLC9A1HPGDALDH1A1HSD17B10
SCHEMBL1437158 0.89 MDM2 (0.47) MDM2MAPTHTTNPSR1GAA
SCHEMBL9893781 0.84 MDM2 (0.60) MDM2HPGDALDH1A1TP53MAPK1
SCHEMBL1437000 0.84 MDM2 (0.46) MDM2SLC9A1HPGDALDH1A1HSD17B10
SCHEMBL9893677 0.83 MDM2 (0.70) MDM2SLC9A1HPGDALDH1A1MAPK1
SCHEMBL1436894 0.83 MDM2 (0.40) MDM2SLC9A1HPGDALDH1A1HSD17B10
SCHEMBL9893616 0.82 MAPT (0.49) MDM2TP53MAPTHTTNPSR1
SCHEMBL9893984 0.82 MDM2 (0.50) MDM2SLC9A1HPGDALDH1A1HSD17B10
SCHEMBL6951731 0.82 MDM2 (0.71) MDM2TP53MAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2470502-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS Novartis AG (CH) 2012-07-04 EP disclosed
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2012-06-14 US disclosed
WO-2011023677-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS NOVARTIS AG (CH) 2011-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149661-A1 TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS MDM4, MDM2, TP53 MDM2 2/4885SLC9A1 4778/4885HPGD 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.